BetterLife Pharma (BETRF) Gains from Sales and Divestitures (2021)
BetterLife Pharma (BETRF) posted Gains from Sales and Divestitures of -$2.4 million for Q1 2021.
Powered by 
Analysis
BetterLife Pharma (BETRF) Gains from Sales and Divestitures (2021) Analysis & Trends
BetterLife Pharma has reported Gains from Sales and Divestitures for 1 years, with the latest figure at -$2.4 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn |
| 10 | BetterLife Pharma | 31.61 Mn | 31.59 Mn | - |